Autosomal dominant myotonia congenita in a Taiwanese family and beneficial response to mexiletine

Acta Neurologica Taiwanica

Volumn 12, Issue 3, 2003, Pages 130-135

  Kuo, Hung Chou ^a   Huang, Chin Chang ^a   Chu, Chun Che ^a   Chiang, Shu Ya ^b   Hsiao, Kuang Ming ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Autosomal dominant myotonia congenita; Mexiletine; Therapeutic response; Thomsen's disease

Indexed keywords

MEXILETINE;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DRUG SAFETY; FEMALE; GENETIC ANALYSIS; HUMAN; MUSCLE RELAXATION; MYOTONIA; MYOTONIC DYSTROPHY; PROGNOSIS; TAIWAN; THOMSEN DISEASE; WALKING;

EID: 0041736280     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Abdalla JA, Casley WL, Cousin HK, et al. Linkage analysis of candidate loci in autosomal dominant myotonia congenita. Neurology 1992;42:1561-4.
2. Fontaine B. Periodic paralysis, myotonia congenita and sarcolemmal ion channels: a success of the candidate gene approach. Neuromusc Disord 1993;3:101-7.
3. George AL Jr, Crackower MA, Abdalla JA, et al. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet 1993;3:305-10.
4. Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257:798-800.
5. Zhang J, Bendahhou S, Sanguinetti MC, et al. Functional consequences of chloride channel gene (CLCN1) mutations causing myotonia congenita. Neurology 2000;54:937-42.
6. Hudson AJ, Ebers GC, Bulman DE. The skeletal muscle and chloride channel diseases. Brain 1995;118:547-63.
7. Hoffman EP. Voltage-gated ion channelopathies: inhibited disorders caused by abnormal sodium, chloride, and calcium regulation in skeletal muscle. Annu Rev Med 1995;46:431-41.
8. Streib EW. Differential diagnosis of myotonic syndromes. Muscle Nerve 1987;10:603-15.
9. Sanders DB. Myotonia congenita with painful muscle contractions. Arch Neurol 1976;33:580-2.
10. Barchi RL. Phenotype and genotype in the myotonic disorders. Muscle Nerve 1998;21:1119-21.
11. Wagner S, Deymeer F, Kurz LL, et al. The dominant chloride channel mutant G200R causing fluctuating myotonia: clinical findings, electrophysiology, and channel pathology. Muscle Nerve 1998;21:1122-8.
12. Ptacek LJ, Ziter FA, Roberts JW, et al. Evidence of genetic heterogenicity among the nondystrophic myotonia. Neurology 1992;42:1064-8.
13. Weckbecker K, Wurz A, Mohammadi B, et al. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord 2000;10:31-9.
14. Harley HG, Brook JD, Rundle SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992;355:545-6.
15. Kwiecinski H, Ryniewicz A, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 1992;86:371-5.
16. Hsiao KM, Lin HM, Pan H, et al. Application of FTA sample collection and DNA purification system on the determination of CTG trinucleotide repeat size by PCR-based Southern blotting. J Clin Lab Anal 1999;13:188-93.
17. Grant R, Sutton DL, Behan PO, et al. Nifedipine in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1987;50:199-206.
18. Mexley RT III. Myotonic muscular dystrophy. In: Rowland LP, DiMauro S, eds. Handbook of Clinical Neurology. Vol 18, New York: Elsevier, 1992:209-59.
19. Sechi GP, Traccis S, Durelli L, et al. Carbamazepine versus diphenylhydantoin in treatment of myotonia. Eur Neurol 1983;22:113-8.
20. Ohtaki E, Komori H, Yamaguchi Y, et al. Successful dantrolene sodium treatment of a patient with myotonia congenita (Thomsen's disease). Acta Paediatr Jpn 1991;33:668-71.
21. Hughes EF, Wilson J. Response to treatment with antihistamines in a family with myotonia congenita. Lancet 1991;337:28-30.